Terms: = Prostate cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Prognosis
11 results:
1. The circHMGCS1-miR-205-5p-erbb3 axis mediated the Sanggenon C-induced anti-proliferation effects on human prostate cancer.
Li J; Cao X; Chu T; Lin K; Chen L; Lv J; Tan Y; Chen M; Li M; Wang K; Zheng Q; Li D
Pharmacol Res; 2023 Jan; 187():106584. PubMed ID: 36462326
[TBL] [Abstract] [Full Text] [Related]
2. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
[TBL] [Abstract] [Full Text] [Related]
3. A structural view of PA2G4 isoforms with opposing functions in cancer.
Stevenson BW; Gorman MA; Koach J; Cheung BB; Marshall GM; Parker MW; Holien JK
J Biol Chem; 2020 Nov; 295(47):16100-16112. PubMed ID: 32952126
[TBL] [Abstract] [Full Text] [Related]
4. Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant erbb380kDa in prostate cancer Progression.
El Maassarani M; Barbarin A; Fromont G; Kaissi O; Lebbe M; Vannier B; Moussa A; Séité P
PLoS One; 2016; 11(5):e0155950. PubMed ID: 27191720
[TBL] [Abstract] [Full Text] [Related]
5. The downregulation of erbb3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Hu B; Xiong Y; Ni R; Wei L; Jiang D; Wang G; Wu D; Xu T; Zhao F; Zhu M; Wan C
Mol Cell Biochem; 2014 Nov; 396(1-2):175-85. PubMed ID: 25081333
[TBL] [Abstract] [Full Text] [Related]
6. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Oleksowicz L; Liu Y; Bracken RB; Gaitonde K; Burke B; Succop P; Levin L; Dong Z; Lu S
Prostate; 2012 Jul; 72(10):1140-9. PubMed ID: 22127954
[TBL] [Abstract] [Full Text] [Related]
7. Heregulin expression and prognosis in prostate adenocarcinoma.
Grimsley SJ; Shini S; Underwood MA; Edwards J
Urol Int; 2011; 87(3):363-8. PubMed ID: 21865659
[TBL] [Abstract] [Full Text] [Related]
8. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract] [Full Text] [Related]
9. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
Wiseman SM; Makretsov N; Nielsen TO; Gilks B; Yorida E; Cheang M; Turbin D; Gelmon K; Huntsman DG
Cancer; 2005 May; 103(9):1770-7. PubMed ID: 15770691
[TBL] [Abstract] [Full Text] [Related]
10. CI-1033, a pan-erbB tyrosine kinase inhibitor.
Slichenmyer WJ; Elliott WL; Fry DW
Semin Oncol; 2001 Oct; 28(5 Suppl 16):80-5. PubMed ID: 11706399
[TBL] [Abstract] [Full Text] [Related]
11. A potential autocrine loop between heregulin-alpha and erbb-3 receptor in human prostatic adenocarcinoma.
Leung HY; Weston J; Gullick WJ; Williams G
Br J Urol; 1997 Feb; 79(2):212-6. PubMed ID: 9052472
[TBL] [Abstract] [Full Text] [Related]
